[go: up one dir, main page]

MXPA05009435A - Metodos de uso y composiciones que contienen medicamentos inhibidores selectivos de citocina para el tratamiento y manejo de alteraciones del sistema nervioso central. - Google Patents

Metodos de uso y composiciones que contienen medicamentos inhibidores selectivos de citocina para el tratamiento y manejo de alteraciones del sistema nervioso central.

Info

Publication number
MXPA05009435A
MXPA05009435A MXPA05009435A MXPA05009435A MXPA05009435A MX PA05009435 A MXPA05009435 A MX PA05009435A MX PA05009435 A MXPA05009435 A MX PA05009435A MX PA05009435 A MXPA05009435 A MX PA05009435A MX PA05009435 A MXPA05009435 A MX PA05009435A
Authority
MX
Mexico
Prior art keywords
nervous system
central nervous
cytokine inhibitory
selective cytokine
methods
Prior art date
Application number
MXPA05009435A
Other languages
English (en)
Inventor
H Schafer Peter
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MXPA05009435A publication Critical patent/MXPA05009435A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen los metodos de tratamiento, prevencion y/o manejo de alteraciones del sistema nervioso central, como la enfermedad de Parkinson, la enfermedad de Alzheimer, el deterioro cognitivo leve, enfermedad de Huntington, esclerosis lateral amitofica, depresion y memoria de largo plazo defectuosa, y sin sindromes relacionados. Los metodos especificos consisten en la administracion de un medicamento inhibidor selectivo de citocina, o una sal, solvato, hidrato, estereoisomero, clatrato aceptado para uso farmaceutico o profarmaco de este, solo o en combinacion con un segundo ingrediente activo. Las composiciones farmaceuticas, sus formas de dosificacion unitaria individuales y los kits convenientes para utilizarlas en los metodos de la invencion tambien estan descritos.
MXPA05009435A 2003-03-06 2004-03-05 Metodos de uso y composiciones que contienen medicamentos inhibidores selectivos de citocina para el tratamiento y manejo de alteraciones del sistema nervioso central. MXPA05009435A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45237403P 2003-03-06 2003-03-06
PCT/US2004/006782 WO2004080393A2 (en) 2003-03-06 2004-03-05 Selective cytokine inhibitory drugs for treating disorders of the central nervous system

Publications (1)

Publication Number Publication Date
MXPA05009435A true MXPA05009435A (es) 2005-11-23

Family

ID=32990646

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009435A MXPA05009435A (es) 2003-03-06 2004-03-05 Metodos de uso y composiciones que contienen medicamentos inhibidores selectivos de citocina para el tratamiento y manejo de alteraciones del sistema nervioso central.

Country Status (12)

Country Link
EP (1) EP1605935A4 (es)
JP (1) JP2006519875A (es)
KR (1) KR100831545B1 (es)
CN (1) CN1780616B (es)
AU (1) AU2004220607B2 (es)
BR (1) BRPI0408113A (es)
CA (1) CA2517845A1 (es)
IL (1) IL170710A0 (es)
MX (1) MXPA05009435A (es)
NZ (1) NZ542408A (es)
WO (1) WO2004080393A2 (es)
ZA (1) ZA200507322B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
CN102905532A (zh) 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
US10159648B2 (en) 2015-05-22 2018-12-25 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
JP2017141222A (ja) * 2016-02-09 2017-08-17 国立大学法人帯広畜産大学 パーキンソン病に併発した認知障害の治療剤及びそのスクリーニング方法
CN111542314B (zh) * 2017-10-18 2023-11-24 内在生物技术有限公司 神经退行性疾病的治疗剂
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
JP2023549174A (ja) * 2020-11-04 2023-11-22 グリアセルテック・インコーポレイテッド クロルプロマジンを含む神経炎症性疾患の予防または治療用組成物
CN119280228B (zh) * 2024-11-06 2025-09-19 桂林医学院附属医院 帕金森病神经保护作用药物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
AR003951A1 (es) * 1995-05-26 1998-09-30 Pfizer Formulacion farmaceutica sinergica para el tratamiento de la enfermedad de parkinson y composiciones para prepararla.
US5728845A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
JP3568749B2 (ja) * 1996-12-17 2004-09-22 株式会社デンソー 半導体のドライエッチング方法
NZ502379A (en) * 1997-07-31 2002-10-25 Celgene Corp Substituted alkanohydroxamic acids and use in pharmaceuticals for reducing TNF-alpha levels
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6471961B1 (en) * 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US20020131954A1 (en) * 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
WO2003080048A1 (en) * 2002-03-20 2003-10-02 Celgene Corporation (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
AU2003262187A1 (en) * 2002-04-12 2003-10-27 Celgene Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system

Also Published As

Publication number Publication date
JP2006519875A (ja) 2006-08-31
KR20050109971A (ko) 2005-11-22
CN1780616A (zh) 2006-05-31
AU2004220607B2 (en) 2009-06-11
IL170710A0 (en) 2011-08-01
WO2004080393A3 (en) 2004-12-02
KR100831545B1 (ko) 2008-05-21
NZ542408A (en) 2009-03-31
CN1780616B (zh) 2010-05-12
BRPI0408113A (pt) 2006-03-01
CA2517845A1 (en) 2004-09-23
AU2004220607A1 (en) 2004-09-23
EP1605935A4 (en) 2009-05-20
WO2004080393A2 (en) 2004-09-23
ZA200507322B (en) 2007-03-28
EP1605935A2 (en) 2005-12-21

Similar Documents

Publication Publication Date Title
WO2005043971A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
WO2005046318A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
WO2005097125A3 (en) Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease
BRPI0315315B8 (es)
WO2000010551A3 (en) Methods of using and compositions comprising dopamine reuptake inhibitors
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
WO2008008474A3 (en) Compositions and methods for the treatment of chronic pain conditions
WO2004037207A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
MXPA05009435A (es) Metodos de uso y composiciones que contienen medicamentos inhibidores selectivos de citocina para el tratamiento y manejo de alteraciones del sistema nervioso central.
MX2007006066A (es) Inhibidores de jnk para el tratamiento de lesiones del snc.
WO2004043378A3 (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
WO2004034962A3 (en) Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
WO2005046593A3 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
MXPA06002722A (es) Composicion farmaceutica que comprende un antagonista del receptor p2x7 y un farmaco anti-inflamatorio no esteroidal.
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
UA103791C2 (uk) Композиція, що включає модулятор pde4, і спосіб її застосування для лікування, профілактики або супроводу туберкульозу
WO2005094218A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
WO2005039497A3 (en) Methods and compositions comprising thalidomide for treatment of fibromyalgia
WO2004041190A3 (en) Composition for the treatment of macular degenration
WO2004037199A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
WO2005065372A3 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
WO2005046594A3 (en) Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
WO2005110085A3 (en) Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
WO2004029025A3 (en) Methods and compositions for the treatment of autoimmune disorders using clofarabine
WO2004041181A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration

Legal Events

Date Code Title Description
FA Abandonment or withdrawal